Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1982 4
1983 3
1984 2
1985 1
1986 2
1987 5
1988 1
1989 3
1990 3
1991 13
1992 24
1993 47
1994 53
1995 54
1996 58
1997 65
1998 57
1999 91
2000 101
2001 122
2002 134
2003 154
2004 149
2005 147
2006 139
2007 196
2008 185
2009 167
2010 192
2011 223
2012 202
2013 178
2014 183
2015 196
2016 148
2017 128
2018 107
2019 38
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

3,150 results
Results by year
Filters applied: . Clear all
Page 1
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B, et al. Lancet Oncol 2016 - Clinical Trial. PMID 27216274
BACKGROUND: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is the standard therapy for physically fit patients with advanced chronic lymphocytic leukaemia. ...The increased frequency of infectious complications with fludarabine, cyclophosphamide, and rituximab was more pronounced in patients older than 65 years. ...
BACKGROUND: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is the standard therapy for physically fit patients …
Selecting Frontline Therapy for CLL in 2018
Jain N. Hematology Am Soc Hematol Educ Program 2018 - Review. PMID 30504317 Free PMC article.
Fludarabine, cyclophosphamide, rituximab chemotherapy remains the standard frontline therapy for young fit patients with CLL, especially if IGHV mutated. ...
Fludarabine, cyclophosphamide, rituximab chemotherapy remains the standard frontline therapy for young fit patients with CLL, especia
Fludarabine and neurotoxicity in engineered T-cell therapy.
Lowe KL, et al. Gene Ther 2018. PMID 29789639
In a similar CAR-T study also incorporating fludarabine in the preconditioning regimen, ZUMA-1 (NCT02348216), one patient died of cerebral edema. However, subsequent deaths in the JCAR-015 study after removal of fludarabine and improved understanding behind the mechanisms of CAR-T-related encephalopathy syndrome (CRES) indicate that fludarabine is not the primary causative agent of cerebral edema and that it can be safely incorporated into the preconditioning regimen for ACT. ...
In a similar CAR-T study also incorporating fludarabine in the preconditioning regimen, ZUMA-1 (NCT02348216), one patient died of cer …
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M, et al. Lancet Oncol 2016 - Clinical Trial. PMID 26655425
BACKGROUND: Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphomas who relapse after alkylating chemotherapy. ...Thus, 219 patients were included in the per-protocol analysis (114 bendamustine plus rituximab, 105 fludarabine plus rituximab). 1-year progression-free survival with bendamustine plus rituximab was 0·76 (95% CI 0·68-0·84) and 0·48 (0·39-0·58) with fludarabine plus rituximab (non-inferiority p<0·0001). ...
BACKGROUND: Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphoma …
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA, et al. Blood 2016. PMID 26492934 Free PMC article.
Fludarabine, cyclophosphamide, and rituximab (FCR) achieved a high response rate, but continued relapses were seen in initial reports. ...
Fludarabine, cyclophosphamide, and rituximab (FCR) achieved a high response rate, but continued relapses were seen in initial reports
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Slatter MA, et al. Biol Blood Marrow Transplant 2018 - Clinical Trial. PMID 29155317 Free article.
Here we report outcomes of 160 children who received homogeneous conditioning with treosulfan, fludarabine, and, in most cases, alemtuzumab (n = 124). ...The combination of treosulfan, fludarabine, and alemtuzumab is associated with excellent results in HSCT for PID....
Here we report outcomes of 160 children who received homogeneous conditioning with treosulfan, fludarabine, and, in most cases, alemt …
(18)F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients.
Chantepie S, et al. J Nucl Med 2018 - Clinical Trial. PMID 29419478 Free article.
The tumor uptake, biodistribution, and radiation dosimetry of (18)F-fludarabine were evaluated. Six successive partial-body PET scans were acquired for 250 min after an intravenous 4 MBq/kg bolus of (18)F-fludarabine. ...The mean effective dose from a mean injected (18)F-fludarabine activity of 305 ± 76 MBq was 3.07 ± 0.81 mSv. Conclusion:(18)F-fludarabine PET might well be a promising tool for lymphoproliferative diseases. ...
The tumor uptake, biodistribution, and radiation dosimetry of (18)F-fludarabine were evaluated. Six successive partial-body PET scans …
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Shanafelt TD, et al. N Engl J Med 2019 - Clinical Trial. PMID 31365801 Free PMC article.
BACKGROUND: Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited. METHODS: In a phase 3 trial, we randomly assigned (in a 2:1 ratio) patients 70 years of age or younger with previously untreated CLL to receive either ibrutinib and rituximab for six cycles (after a single cycle of ibrutinib alone), followed by ibrutinib until disease progression, or six cycles of chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. ...
BACKGROUND: Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarab
3,150 results
Jump to page
Feedback